Transgene Extends its myvac® Platform, Further Establishing its Position as a Key Player in the Rapidly Emerging Individualized Cancer Immunotherapy Field

2026 Half-Year Results and Business Update

myvac® – Expanding potential across solid tumors through viral vector, AI driven neoantigen selection, and scalable cell-line manufacturing